List of Excipients in Branded Drug MOTEGRITY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Takeda Pharmaceuticals America Inc	MOTEGRITY	prucalopride	54092-546	CELLULOSE, MICROCRYSTALLINE
Takeda Pharmaceuticals America Inc	MOTEGRITY	prucalopride	54092-546	HYPROMELLOSE 2910
Takeda Pharmaceuticals America Inc	MOTEGRITY	prucalopride	54092-546	LACTOSE MONOHYDRATE

Motegrity Excipient Strategy and Commercial Opportunities for Prucalopride

Last updated: August 26, 2026

Motegrity contains prucalopride succinate, a selective 5-HT4 receptor agonist approved in the United States for chronic idiopathic constipation in adults. Its immediate-release film-coated tablet uses a conventional excipient system: lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, hypromellose, triacetin and colorants. The strongest commercial opportunities are generic tablets, lactose-free reformulations, orally disintegrating tablets, pediatric liquid products and differentiated gastrointestinal delivery systems.

The central development issue is not active pharmaceutical ingredient availability. It is achieving bioequivalence while improving administration, excipient tolerability, manufacturing efficiency or patient convenience without creating a new clinical or regulatory burden.

What excipients are used in Motegrity tablets?

Motegrity is marketed as 1 mg and 2 mg film-coated tablets containing prucalopride succinate. The FDA labeling identifies the following inactive ingredients:

Product element	Motegrity excipients	Primary function
Tablet core	Lactose monohydrate	Diluent and compression aid
Tablet core	Microcrystalline cellulose	Filler, dry binder and disintegration support
Tablet core	Colloidal silicon dioxide	Glidant and flow aid
Tablet core	Magnesium stearate	Lubricant
Film coating	Hypromellose	Film-forming polymer
Film coating	Triacetin	Plasticizer
Film coating	Titanium dioxide and colorants	Opacity and product identification

The marketed composition is consistent with a low-dose, immediate-release tablet. Because the prucalopride dose is small relative to the tablet mass, content uniformity, powder segregation and blend homogeneity are critical manufacturing controls.

The product does not require a modified-release matrix, enteric coating or specialized gastrointestinal targeting system. A substitute formulation should preserve rapid release and comparable systemic exposure unless it is developed as a separate differentiated product.

Source: U.S. Food and Drug Administration, Motegrity prescribing information.[1]

How does the Motegrity excipient system affect generic development?

A conventional generic tablet can use the reference formulation as its starting point, but exact excipient duplication is not mandatory. The developer must demonstrate pharmaceutical equivalence and bioequivalence under the applicable abbreviated new drug application pathway.

The principal formulation risks are:

1. Low-dose uniformity. Prucalopride is present at 1 mg or 2 mg, creating a high dilution ratio. Geometric dilution, controlled particle-size distribution and blend sampling are important.

2. Dissolution sensitivity. Magnesium stearate concentration and lubrication time can affect wetting and dissolution. Excessive lubrication may delay release.

3. Compression behavior. Lactose and microcrystalline cellulose provide a workable direct-compression platform, but changes in grade, moisture and particle size can alter hardness, friability and disintegration.

4. Moisture control. Lactose, microcrystalline cellulose and the film coating have different moisture characteristics. Packaging selection can affect tablet stability and appearance.

5. Color matching. Film-coat color is not normally a principal therapeutic issue, but a close visual match can reduce substitution friction and support product identification.

6. Excipient sensitivity. Lactose may create a commercial barrier for patients with lactose intolerance or for buyers seeking lactose-free products, although the amount in a tablet is usually small.

The lowest-risk strategy is a Q1/Q2-oriented formulation using the same qualitative excipients and comparable quantitative levels. A developer seeking commercial differentiation can move away from the reference composition, but that increases formulation, dissolution and regulatory risk.

What commercial opportunities exist for Motegrity excipient reformulation?

Lactose-free prucalopride tablets

A lactose-free tablet is the most straightforward differentiation opportunity. Lactose could be replaced with mannitol, dibasic calcium phosphate, anhydrous lactose-free fillers or specialized co-processed excipients.

Mannitol is attractive for its mouthfeel and compatibility with orally disintegrating dosage forms. Dibasic calcium phosphate can improve compactability but may change dissolution and increase tablet density. A co-processed filler-binder can simplify direct compression and improve content uniformity at low drug load.

The commercial value depends on whether the product is positioned for:

• Patients avoiding lactose-containing medicines
• Pharmacy and hospital formularies
• International markets with different excipient preferences
• A branded-generic strategy
• A pediatric or geriatric product

A lactose-free product is unlikely to support a premium by itself in a crowded generic market. It becomes more valuable when combined with a different administration route or a documented tolerability advantage.

Orally disintegrating tablets

An orally disintegrating tablet could address patients with swallowing difficulty, older adults and patients who prefer administration without water. Mannitol, crospovidone, croscarmellose sodium and low-substituted hydroxypropyl cellulose are common development options.

The key technical targets are:

• Disintegration within the applicable regulatory limit
• Adequate mechanical strength
• Low friability
• Acceptable taste and mouthfeel
• Stable prucalopride content under humidity stress
• Comparable exposure to the immediate-release tablet

Prucalopride has a pharmacological effect that does not require rapid buccal absorption. The product therefore should be designed to disintegrate in the oral cavity and then release the drug for gastrointestinal absorption rather than to create a sublingual delivery claim.

An orally disintegrating formulation could support a 505(b)(2) strategy if it introduces a meaningful dosage-form change, although the regulatory pathway would depend on the product’s formulation, labeling and reliance on existing findings. A generic ODT may instead require an ANDA if the applicable legal and pharmaceutical-equivalence requirements are met.

Oral liquid or powder-for-reconstitution products

A liquid or reconstitutable powder could expand use in pediatric populations, although chronic idiopathic constipation labeling and pediatric development requirements would need to be addressed separately. Suitable excipient systems may include:

• Purified water
• Buffering agents
• Suspending agents
• Sweeteners
• Flavoring agents
• Preservatives, where justified
• Chelating agents or antioxidants, if stability requires them

Prucalopride solubility, chemical stability, taste and preservative compatibility would determine the commercial feasibility. A suspension can reduce solubility demands but increases dose-uniformity and redispersibility requirements.

A liquid product could have greater differentiation than a lactose-free tablet, but it would carry higher development and supply-chain costs. Bottle, dosing syringe and in-use stability requirements also increase complexity.

Sprinkle or sachet formulations

A granule or sachet product could target patients who cannot swallow tablets. The main options would be:

• Immediate-release granules
• Granules dispersed in water
• Granules sprinkled on soft food
• Powder for oral suspension

Taste masking becomes more important because the dosage form may expose particles directly to the mouth. Polymer coating, lipid coating or ion-exchange approaches could protect against bitterness, but each may affect release and bioequivalence.

This format could create an intellectual-property position around particle coating, multiparticulate manufacture or administration with food. The value of that position would depend on whether the claims cover a clinically relevant formulation rather than a routine excipient substitution.

What formulation patents could protect a prucalopride product?

Excipient substitutions alone often provide weak patent protection. A stronger formulation estate would generally require a measurable technical feature and a defined performance result.

Potential claim categories include:

Claim category	Potential protected subject matter	Commercial relevance
Composition	Specific prucalopride-to-excipient ratio or excipient combination	Supports product differentiation but can be designed around
Particle engineering	Defined particle-size distribution or surface treatment	May improve content uniformity or dissolution
ODT formulation	Superdisintegrant, porosity, hardness and disintegration profile	Supports patient-convenience positioning
Taste masking	Coated particles or polymer-lipid barriers	Relevant to pediatric and ODT products
Liquid formulation	pH range, preservative system and stability profile	Supports pediatric or swallowing-impaired use
Manufacturing process	Blend order, granulation, lubrication or coating parameters	Can protect process know-how and reduce manufacturing variability
Packaging	Moisture-barrier system or desiccant configuration	Usually stronger as trade secret or quality know-how than as a broad patent

A patent strategy should link the formulation to a measurable result, such as improved stability, reduced degradation, faster disintegration, reduced variability or acceptable taste. Broad claims covering “prucalopride and a pharmaceutically acceptable excipient” would face substantial validity and enablement risks.

The original prucalopride compound patent estate is distinct from later formulation protection. Compound patents generally do not prevent a generic manufacturer from using a different excipient system after compound protection expires. Later patents may cover specific salts, dosage forms, manufacturing processes or methods of use.

When does Motegrity lose exclusivity?

Motegrity was approved by the FDA in December 2018 for the treatment of chronic idiopathic constipation in adults.[2] FDA approval does not by itself establish the end of all commercial exclusivity. Patent expiration, regulatory exclusivity, pediatric extensions and listed patent status must be evaluated separately.

Exclusivity category	Motegrity relevance
New chemical entity exclusivity	The product was approved with an active ingredient not previously approved in the United States; the applicable NCE period generally runs for five years from approval
ANDA submission restriction	During the first four years of NCE exclusivity, an ANDA generally cannot be submitted unless it includes a Paragraph IV certification
Patent protection	Depends on issued patents, listed patents and any relevant patent-term adjustment or extension
Pediatric exclusivity	Adds six months only if granted after completion of an FDA-required pediatric program
Method-of-use protection	May affect labeling and carve-out strategy if listed and enforceable
Regulatory exclusivity outside the United States	Varies by jurisdiction

A commercial launch date cannot be inferred from the approval date alone. Generic entry depends on the operative patent and exclusivity barriers, ANDA review, Paragraph IV litigation and any settlement terms.

What is the Orange Book status of Motegrity?

Motegrity is associated with NDA 210166 in FDA approval materials.[2] The Orange Book is the controlling public source for current listed patents, exclusivity codes and therapeutic-equivalence information.[3]

For a prucalopride generic, the legal review should cover:

• Patent listings associated with NDA 210166
• Expiration dates and patent-term adjustments
• Any use codes attached to method-of-use patents
• Whether a Paragraph IV certification is required
• Whether a Section viii statement could omit a patented use
• Any 30-month stay triggered by patent litigation
• First-filer status and possible 180-day exclusivity

The absence of a formulation patent does not eliminate litigation risk. A branded company may assert method-of-use, manufacturing or later-issued formulation patents. Conversely, a listed patent may have limited commercial effect if the generic label can omit the protected indication or if the patent is vulnerable to invalidity or non-infringement defenses.

Which companies are challenging Motegrity?

Prucalopride is a small-molecule drug, so the relevant competitive threats are conventional generic manufacturers rather than biosimilar developers. Potential competitors include companies with ANDA portfolios in gastrointestinal products, specialty generics and chronic constipation therapies.

Publicly confirmed Paragraph IV challengers, litigation outcomes and settlement terms should be determined from FDA records, federal court dockets and company filings. A generic entrant’s commercial position will depend on:

• The date of ANDA filing
• Paragraph IV certification status
• First-filer position
• Product strengths offered
• Manufacturing capacity
• Pharmacy distribution
• Formulary access
• Whether the entrant offers only tablets or a differentiated dosage form

A biosimilar pathway does not apply because prucalopride is a chemically synthesized small molecule, not a biologic subject to the Biologics Price Competition and Innovation Act.

How strong is the Motegrity patent estate?

The commercial strength of the estate depends more on surviving, enforceable later patents than on the original compound patent. For an established small-molecule product, the most relevant layers are:

1. The prucalopride compound and salt.
2. Approved-use and method-of-treatment claims.
3. Specific tablet, ODT, liquid or multiparticulate formulations.
4. Manufacturing and purification processes.
5. Pediatric or new-indication protection.

A broad composition patent covering a routine tablet with ordinary pharmaceutical excipients would be comparatively vulnerable. A narrowly claimed formulation may be stronger if it solves a documented technical problem, but it may also be easier to design around.

The practical patent risk is therefore formulation-specific. A conventional immediate-release generic may face lower technical barriers than an ODT, liquid or taste-masked product, even if the differentiated product has more potential patent claims.

How does Motegrity compare with competing constipation drugs?

Motegrity competes with osmotic laxatives, stimulant laxatives, chloride-channel activators and guanylate cyclase-C agonists. Excipient opportunities differ by product class.

Product category	Example	Excipient opportunity	Competitive implication
5-HT4 agonist	Prucalopride	ODT, liquid, lactose-free tablet	Differentiation through administration and adherence
Chloride-channel activator	Lubiprostone	Softgel or capsule reformulation	Less direct tablet competition
GC-C agonist	Linaclotide	Capsule, delayed release and stability systems	Stronger formulation complexity
GC-C agonist	Plecanatide	Tablet or oral dosage-form innovation	Dose and stability differentiation
Osmotic laxative	Polyethylene glycol	Powder, sachet and flavor systems	Low-cost competition and convenience
Stimulant laxative	Bisacodyl	Enteric coating and combination products	Release-site and tolerability positioning

Motegrity’s immediate-release tablet platform is technically simpler than the enteric or delayed-release systems used for some competing agents. That simplicity lowers generic manufacturing barriers but also limits the defensibility of routine excipient changes.

What generic launch scenarios exist for prucalopride?

Scenario 1: Standard immediate-release tablet

This is the most probable first generic strategy. It uses a conventional tablet core, targets the reference dissolution profile and competes primarily on price, supply reliability and contracting.

Scenario 2: Tablet with improved excipient profile

A lactose-free or low-allergen tablet could support a branded-generic launch. The product would need a clear purchasing rationale because most payers treat therapeutically equivalent tablets similarly.

Scenario 3: Orally disintegrating tablet

An ODT could support a differentiated product with potential 505(b)(2) or other regulatory treatment, depending on the final claims and equivalence strategy. The opportunity is stronger in self-pay, specialty pharmacy and adherence-focused channels than in commodity generic tenders.

Scenario 4: Pediatric or swallowing-impaired formulation

A liquid, suspension or sprinkle product could create a less crowded niche. The development program would be more expensive and would require careful age-appropriate excipient selection.

Scenario 5: Combination or co-pack strategy

A prucalopride product could be paired commercially with bowel-regimen products, although a fixed-dose combination would introduce additional clinical and regulatory requirements. A co-pack or adherence kit may be simpler but would provide weaker patent protection.

What manufacturing and IP barriers affect commercial opportunity?

The main manufacturing barriers are low-dose uniformity, blend segregation, dissolution control and moisture stability. These are manageable with standard solid-dose technology but can become material at scale.

A development program should establish:

• A controlled prucalopride particle-size specification
• Blend uniformity across commercial batch sizes
• Lubrication controls
• Disintegration and dissolution limits
• Film-coat weight-gain controls
• Moisture-barrier packaging requirements
• Stability under ICH conditions
• Excipient supplier qualification
• A dual-source plan for critical excipients

The main IP barriers are patent-specific rather than excipient-specific. A manufacturer can often avoid a formulation patent by changing filler type, coating composition, process parameters or dosage-form architecture. Such changes must not compromise bioequivalence, manufacturability or regulatory status.

Geographic coverage also matters. U.S. approval, European authorization and national generic procedures may involve different reference products, patent registers, data-exclusivity periods and labeling requirements. An excipient strategy optimized for the United States may require modification for Europe, Canada, Japan or emerging markets.

What is the revenue exposure and commercial value of a Motegrity generic?

Revenue exposure depends on the branded product’s prescription volume, net price, payer restrictions and the timing of generic entry. A standard generic usually faces rapid price erosion after multiple entrants. A differentiated dosage form can preserve higher net pricing but has a smaller addressable market and higher launch costs.

The most attractive commercial sequence is generally:

1. Launch a standard 1 mg and 2 mg tablet if legally and economically feasible.
2. Use the same manufacturing platform to develop a lactose-free version.
3. Add an ODT or sprinkle product if clinical demand and intellectual-property protection justify investment.
4. Pursue pediatric or liquid development only where the market supports the additional regulatory cost.

The commercial case for excipient innovation is strongest when the reformulation solves a documented patient or channel problem. Changing lactose to another filler without a meaningful usability, supply or tolerability benefit is unlikely to support durable pricing power.

Key Takeaways

• Motegrity contains prucalopride succinate in a conventional immediate-release film-coated tablet.
• The core excipients are lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate.
• The leading near-term generic opportunity is a conventional 1 mg and 2 mg tablet with controlled low-dose uniformity and comparable dissolution.
• Lactose-free tablets offer a practical but limited differentiation route.
• Orally disintegrating, liquid and sprinkle formulations have greater commercial differentiation but higher regulatory and manufacturing risk.
• Routine excipient substitutions generally provide weak patent protection unless tied to a measurable technical result.
• Prucalopride is a small molecule, so biosimilar competition is not relevant.
• Current patent, Orange Book and Paragraph IV conclusions depend on the operative FDA listings, court records and regulatory exclusivity status.
• A successful commercial strategy should separate low-risk generic entry from higher-value dosage-form innovation.

FAQs

Can Motegrity tablets be reformulated without lactose?

Yes. Lactose can be replaced with mannitol, microcrystalline cellulose, calcium phosphate or a co-processed filler-binder, subject to pharmaceutical equivalence, stability and bioequivalence requirements.

Is prucalopride suitable for an orally disintegrating tablet?

Yes. The low dose and immediate-release profile are compatible with an ODT platform. The principal development issues are taste, mechanical strength, disintegration, moisture protection and systemic bioequivalence.

Does prucalopride require an enteric coating?

No. Motegrity is an immediate-release film-coated tablet. An enteric formulation would be a separate product concept requiring a technical and regulatory rationale.

Can an excipient change create a new prucalopride patent?

It can, but a patent is more defensible when the excipient combination produces an unexpected or measurable benefit, such as improved stability, faster disintegration, reduced variability or taste masking.

Are biosimilars a competitive threat to Motegrity?

No. Prucalopride is a chemically synthesized small molecule. The relevant competitors are ANDA-based generic tablets and potentially differentiated 505(b)(2) dosage forms.

References

1. U.S. Food and Drug Administration. (2023). Motegrity (prucalopride succinate) tablets prescribing information. Takeda Pharmaceuticals USA, Inc.

2. U.S. Food and Drug Administration. (2018). FDA approves Motegrity for chronic idiopathic constipation in adults. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.

5. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.

6. International Council for Harmonisation. (2019). M9: Biopharmaceutics classification system-based biowaivers. ICH.